zu rasch. Aber wir haben auch besondere Zeit, Covid-Zeit. Wenn die Zulassung Ende des Monats kommt, springt der Kurs durch die Decke. Wenn nicht, werden die, die jetzt einsteigen, rote Zahlen sehen.

https://finance.yahoo.com/m/...7aaf7c6e922/is-ocugen-a-buy-after.html

https://www.bharatbiotech.com/covaxin.html

• Phase 3 multi-centre trial: The first dose of vaccination has been given to all the participants and presently, second dose of either vaccine/placebo is being administered.

• Efficacy is estimated by the incidence of COVID-19 cases accrual between the vaccine and the placebo group, which will commence two weeks after the second dose. 




• The interim efficacy estimate will be generated by the end of Feb, 2021.